Swiss National Bank Grows Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Swiss National Bank boosted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 22.5% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 85,400 shares of the company's stock after purchasing an additional 15,700 shares during the period. Swiss National Bank owned approximately 0.13% of Vera Therapeutics worth $3,612,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of VERA. AlphaQuest LLC purchased a new stake in Vera Therapeutics during the fourth quarter worth $34,000. KBC Group NV boosted its stake in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock worth $105,000 after acquiring an additional 1,387 shares in the last quarter. Moors & Cabot Inc. acquired a new stake in shares of Vera Therapeutics during the 4th quarter valued at about $220,000. E Fund Management Co. Ltd. increased its stake in shares of Vera Therapeutics by 22.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company's stock valued at $262,000 after purchasing an additional 1,130 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Vera Therapeutics by 109.4% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 9,407 shares of the company's stock valued at $416,000 after purchasing an additional 4,914 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company's stock.

Vera Therapeutics Trading Up 0.4 %

Vera Therapeutics stock traded up $0.11 during midday trading on Friday, hitting $26.63. 530,032 shares of the stock were exchanged, compared to its average volume of 760,878. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -10.20 and a beta of 1.17. The stock's 50-day simple moving average is $30.93 and its 200 day simple moving average is $38.87. Vera Therapeutics, Inc. has a fifty-two week low of $25.55 and a fifty-two week high of $51.61.

Remove Ads

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. On average, equities analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Guggenheim raised their price objective on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Wolfe Research assumed coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price on the stock. JPMorgan Chase & Co. dropped their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $64.67.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of the business's stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total value of $730,450.00. Following the sale, the chief executive officer now directly owns 143,603 shares in the company, valued at approximately $5,993,989.22. The trade was a 10.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 21.70% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.